

COMPANY OVERVIEW

VistaGen Therapeutics (Nasdaq: VTGN) is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medicines that go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen's three CNS drug candidates, PH94B, PH10, and AV-101, has a differentiated mechanism of action, a favorable safety profile in all clinical studies to date, and therapeutic potential in multiple CNS markets.

RECENT NEWS

VistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial Officer

May 4 2021, 8:00 AM EDT

STOCK OVERVIEW

Symbol	VTGN
Exchange	Nasdaq
Market Cap	407.03m
Last Price	\$2.14
52-Week Range	\$0.35 - \$3.18

05/14/2021 04:00 PM EDT

INVESTOR RELATIONS

VistaGen Therapeutics, Inc.
Mark A. McPartland
Vice President, Corporate Development
and Investor Relations
(650) 577-3606
markmcp@vistagen.com

MANAGEMENT TEAM

Shawn K. Singh, J.D.
Chief Executive Officer and Director

H. Ralph Snodgrass, Ph.D.
Founder, President, Chief Scientific Officer
and Director

Mark A. Smith, M.D., Ph.D.
Chief Medical Officer

Ann Cunningham, MBA
Chief Commercial Officer and Director

Jerrold D. Dotson, CPA
Vice President, Chief Financial Officer and
Secretary

Mark J. Ginski, Ph.D.
Senior Vice President, Head of CMC

Mark A. McPartland
Vice President of Corporate Development

Louis Monti, M.D., Ph.D.
Vice President, Translational Medicine

VISTAGEN THERAPEUTICS, INC.

343 Allerton Avenue
South San Francisco, CA 94080

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.